<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948426</url>
  </required_header>
  <id_info>
    <org_study_id>170011</org_study_id>
    <secondary_id>17-C-0011</secondary_id>
    <nct_id>NCT02948426</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer</brief_title>
  <official_title>Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Ovarian cancer is a leading cause of cancer death in women. Monocytes are white blood cells
      that slow tumor growth. Interferons (IFNs) are molecules that help immune cells fight cancer.
      Researchers want to stimulate monocytes with IFNs. They want to test if these stimulated
      monocytes combined with the drugs Sylatron and Actimmune can shrink tumors and slow the
      progression of cancer.

      Objective:

      To test how well IFN stimulated monocytes, with Sylatron and Actimmune, kill tumor cells.

      Eligibility:

      Women ages 18 and older with certain ovarian, fallopian tube, or peritoneal cancers

      Design:

      Participants will be screened with:

      Medical history

      Physical exam

      Blood and urine tests

      Scan

      Results or sample from previous biopsy

      Participants may have a tumor sample taken.

      Participants who do not have a port will have a catheter placed inside the abdominal cavity.
      It will be used to give the treatment.

      Participants will have visits for 4 days of each 28-day cycle. This includes overnight
      observation.

      Participants with ascites fluid in their abdominal cavity will have it sampled twice.

      Each cycle, participants will have:

      Blood tests

      Leukapheresis. Some blood is removed and put through a machine that separates out the
      monocytes. The rest of the blood is returned to the body.

      Infusion of the monocytes and study drugs

      Participants will have weekly phone calls in Cycle 1 and scans every 2 cycles.

      Participants will continue treatment until they can no longer tolerate it or their cancer
      gets worse.

      Participants will have a visit about 1 month after stopping treatment, then monthly phone
      calls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Monocytes can differentiate into classic M1 macrophages inhibiting tumor proliferation
           and promoting natural killer (NK) cell differentiation.

        -  Human alpha interferons (interferon alfa, IFN-alpha), interferon gamma (IFN-gamma) and
           monocytes have strong anti-neoplastic response in vitro and in vivo

        -  IFN-alpha and IFN-gamma have been shown in early phase clinical trials to be safely
           administered intraperitoneally.

        -  Intraperitoneal monocytes alone or activated with IFN-gamma are safe and feasible as
           demonstrated in phase I clinical studies.

        -  We have shown that the combination of human monocytes, IFN-alpha2a and IFN-gamma1b, or
           pegylated IFN-alpha, act synergistically against tumor cells in vitro and in mouse
           models.

      Objectives:

      -To identify a maximum tolerated dose of intraperitoneal autologous monocytes and Sylatron(R)
      (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b).

      Eligibility:

        -  Advanced metastatic or unresectable epithelial ovarian cancer, primary peritoneal cancer
           or fallopian tube cancer that is relapsed and resistant or refractory to prior
           platinum-based standard care systemic regimen.

        -  Patients must be off prior chemotherapy, radiation therapy, hormonal therapy or
           biological therapy for at least 4 weeks.

        -  ECOG performance status 0-1 and adequate organ and marrow function.

      Design:

        -  This is an open label single arm phase I trial to determine the maximum tolerated dose
           of intraperitoneal monocytes and Sylatron(R) (Peginterferon alfa-2b) and Actimmune(R)
           (Interferon gamma-1b).

        -  Autologous monocytes obtained through apheresis will be mixed with Sylatron(R)
           (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b) in a 3 + 3 dose
           escalation and administered intraperitoneally once every 28 days. A new product will be
           manufactured for each treatment cycle.

        -  Once the maximum tolerated dose is obtained, an expansion cohort will be enrolled to
           better quantify response rate and time to disease progression.

        -  Research samples including peripheral blood and ascites will be obtained prior to the
           initiation of study therapy andprior to the start of each cycle. Tissue biopsies will be
           obtained in the dose expansion phase to characterize the immune infiltration.

        -  Patients will be evaluated every 2 cycles for response using RECIST v1.1 and every cycle
           for safety using CTCAE v4.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 27, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of intraperitoneal autologous monocytes and Sylatron (Peginterferon alpha-2b) and Actimmune (Interferon gamma-1b).</measure>
    <time_frame>Cycle 1 Day 28</time_frame>
    <description>Maximum Tolerated Dose of intraperitoneal autologous monocytes and Sylatron (Peginterferon alpha-2b) and Actimmune (Interferon gamma-1b).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 2 cycles</time_frame>
    <description>overall response rate including complete response and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Date of disease progression</time_frame>
    <description>time from the date of start of treatment to progression of disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>ES1 Phase 1 Dose Escalation Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EX1 Dose Expansion Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 additional patients will be treated at the MTD</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Monocytes + ACTIMMUNE + SYLATRON</intervention_name>
    <description>The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the MTD.</description>
    <arm_group_label>ES1 Phase 1 Dose Escalation Arm</arm_group_label>
    <arm_group_label>EX1 Dose Expansion Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Patients must have histologically or cytologically confirmed advanced metastatic or
             unresectable epithelial ovarian cancer, primary peritoneal cancer or fallopian tube
             cancer that is relapsed and resistant (recurred less than 6 months after chemotherapy)
             or refractory (progressed on chemotherapy) to prior platinum- and taxane-based
             standard care systemic regimen. Or patients who are eligible for aditional platinum
             therapy. Histopathologic diagnosis must be confirmed in the Laboratory of Pathology
             (LP), NCI.

          -  Patients must have measurable or evaluable disease. Measurable disease is defined as
             at least one lesion that can be accurately measured in at least one dimension (longest
             diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as
             greater than or equal to 20 mm with conventional techniques or as greater than or
             equal to 10 mm with spiral CT scan.

          -  Patients must be at least 4 weeks from previous therapy (chemotherapy, hormonal
             therapy, and radiation therapy, immunotherapy and monoclonal antibodies, alternative
             therapy or investigational therapeutic agents). There is no limitation on the amount
             of prior therapies allowed. Patients with ovarian cancer 4 weeks from previous therapy
             have been found to have normal monocyte function (unpublished).

          -  Patients who have had cranial radiation therapy need to have completed it greater than
             or equal to 8 weeks prior to enrollment.

          -  Patients are permitted to receive investigational imaging agents while on study.

          -  Patients who have had major surgery must be fully recovered and require a recovery
             period of greater than or equal to 4 weeks prior to enrolling on study.

          -  Age greater than or equal to 18 years. Because no dosing or adverse event data are
             currently available on the use of intraperitoneal monocytes, IFN-alpha 2 or IFN-gamma
             in patients &lt;18 years of age, children are excluded from this study, but will be
             eligible for future pediatric trials.

          -  ECOG performance status less than or equal to 1 (Karnofsky greater than or equal to
             70%).

          -  Adequate renal function, defined as serum creatinine less than or equal to 1.5 X upper
             limit of normal(ULN), or measured creatinine clearance greater than or equal to 60
             mL/min/1.73m^2.

          -  Adequate hepatic function, defined as AST and ALT levels less than or equal to 3 X ULN
             and total bilirubin &lt; 1.5 X ULN, unless known diagnosis of Gilbert s syndrome, where
             bilirubin less than or equal to 5 mg/dl will be permitted. Gilbert s syndrome will be
             defined as elevated unconjugated bilirubin, with conjugated (direct) bilirubin within
             the normal range and less than 20% of the total. Total bilirubin will be permitted up
             to 5 mg/dl, if patients have historical readings consistent with the definition of
             Gilbert s syndrome prior to entering study.

          -  Adequate bone marrow function, defined as absolute neutrophil (ANC) greater than or
             equal to 1,500/mm^3 (greater than or equal to 1.5 X106/L), platelet count greater than
             or equal to 75,000/mm3 (greater than or equal to 75 X10^6/L), and hemoglobin greater
             than or equal to 10 g/dL (transfusion to obtain hemoglobin greater than or equal to 10
             g/dL within 24 hours prior to dosing is allowed).

          -  The effects of intraperitoneal monocytes, IFN-alpha 2, and IFN-gamma on the developing
             human fetus are unknown. For this reason and because interferons based on animal data
             may cause fetal harm, women of child-bearing potential (excludes women with recurrent
             ovarian cancer) and men must agree to use adequate contraception (hormonal or barrier
             method of birth control; abstinence) prior to study entry and for the duration of
             study participation. Should a woman become pregnant or suspect she is pregnant while
             she is participating in this study, she should inform her treating physician
             immediately.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Patients who are receiving any other investigational agents (with exception of imaging
             agents as indicated above in the inclusion criteria).

          -  Patients cannot have previously been treated with interferons (e.g., for chronic
             active hepatitis).

          -  Patients with metastasis outside of the abdominal cavity as we are only giving
             intraperitoneal therapy and we are unsure whether our therapy would be beneficial to
             patients with other metastatic disease except

             --Disease outside of the abdomen that is non-measurable by Recist criteria will be
             allowed.

          -  Lack of recovery of prior adverse events to Grade less than or equal to 1 severity
             (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]
             v 4.03) (except alopecia) due to therapy administered prior to the initiation of study
             drug dosing. Stable persistent grade 2 peripheral neuropathy may be allowed as
             determined on a case-bycase basis at the discretion of the Investigator as interferon
             has not been shown to cause or exacerbate peripheral neuropathy.

          -  Patients with active infection will not be eligible, but may become eligible once
             infection has resolved and at least 7 days have elapsed after antibiotics use was
             completed.

          -  Concomitant chronic (daily or almost daily for greater than or equal to 1 month prior)
             use of steroids or non-steroidal anti-steroidal anti-inflammatory drugs NSAIDS.

          -  Patients with a recent history (within last 5 years) of autoimmune disease or
             inflammatory diseases will be excluded, because interferons may worsen these
             conditions. Exceptions will be allowed for vitiligo and hypothyroidism that has been
             stable on thyroid replacement medications for &gt;6 weeks.

          -  Impaired cardiac function or clinically significant cardiac disease including the
             following:

               -  New York Heart Association class III or IV congestive heart failure

               -  Myocardial infarction within the last 12 months

               -  Subjects known to have impaired LVEF according to institutional standards

          -  History of allergic reactions attributed to compounds of chemical or biologic
             composition similar to interferons or other agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations within the last 12 months that
             would limit compliance with study requirements. Patients with history of
             neuropsychiatric disorders or Major Depressive Disorder (DSM 5 definition:
             http://dsm.psychiatryonline.org/doi/full/10.1176/appi.books.9780890425596.dsm04)
             requiring medical treatment will not be eligible to enroll, based on the black box
             warning (SYLATRON (peginterferon alfa-2b) for injection, for subcutaneous use. Merck
             Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, NJ).
             Exception to this is if patients experienced transient post-partum depression that
             resolved and patient has been off treatment for &gt;10 years. Patients who are taking
             oral anti-depressants for normal sadness, bereavement, or grief will not be excluded.

          -  Pregnant women are excluded from this study because interferons based on animal data
             may cause fetal harm. Because there is an unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother with interferons,
             breastfeeding should be discontinued if the mother is treated with intraperitoneal
             interferons. These potential risks may also apply to other agents used in this study.

          -  Patients on combination antiretroviral therapy for the treatment of HIV are ineligible
             because of the potential for pharmacokinetic interactions with interferons alfa and
             gamma.

          -  Patients receiving any medications or substances that are potent inhibitors or
             inducers of CYP1A2 or CYP2D6 are ineligible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina M Annunziata, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Ekwede, R.N.</last_name>
    <phone>(240) 760-6126</phone>
    <email>ekwedeib@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact National Cancer Institute Referral Office</last_name>
      <phone>888-624-1937</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2017-C-0011.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Johnson CL, Green DS, Zoon KC. Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin. J Interferon Cytokine Res. 2015 Jan;35(1):55-62. doi: 10.1089/jir.2014.0057. Epub 2014 Jul 28.</citation>
    <PMID>25068849</PMID>
  </reference>
  <reference>
    <citation>Soderquest K, Powell N, Luci C, van Rooijen N, Hidalgo A, Geissmann F, Walzer T, Lord GM, Mart√≠n-Fontecha A. Monocytes control natural killer cell differentiation to effector phenotypes. Blood. 2011 Apr 28;117(17):4511-8. doi: 10.1182/blood-2010-10-312264. Epub 2011 Mar 9. Erratum in: Blood. 2013 Sep 26;122(13):2290.</citation>
    <PMID>21389319</PMID>
  </reference>
  <reference>
    <citation>Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015 Jan 15;517(7534):293-301. doi: 10.1038/nature14189. Review.</citation>
    <PMID>25592534</PMID>
  </reference>
  <verification_date>December 6, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Adoptive Cell Therapy</keyword>
  <keyword>Carcinomatosis</keyword>
  <keyword>CA125</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

